Home | About | Journals | Submit | Contact Us | Français |

**|**PLoS Comput Biol**|**v.8(11); 2012 November**|**PMC3486866

Formats

Article sections

Authors

Related links

PLoS Comput Biol. 2012 November; 8(11): e1002758.

Published online 2012 November 1. doi: 10.1371/journal.pcbi.1002758

PMCID: PMC3486866

Jason A. Papin, Editor^{}

University of Virginia, United States of America

* E-mail: patil/at/embl.de

The authors have declared that no competing interests exist.

Conceived and designed the experiments: KRP ARB. Performed the experiments: ARB SA. Analyzed the data: ARB KRP CDM. Contributed reagents/materials/analysis tools: ARB SA KRP CDM. Wrote the paper: ARB KRP.

Received 2012 March 1; Accepted 2012 September 11.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been cited by other articles in PMC.

Genome-scale metabolic networks provide a comprehensive structural framework for modeling genotype-phenotype relationships through flux simulations. The solution space for the metabolic flux state of the cell is typically very large and optimization-based approaches are often necessary for predicting the active metabolic state under specific environmental conditions. The objective function to be used in such optimization algorithms is directly linked with the biological hypothesis underlying the model and therefore it is one of the most relevant parameters for successful modeling. Although linear combination of selected fluxes is widely used for formulating metabolic objective functions, we show that the resulting optimization problem is sensitive towards stoichiometry representation of the metabolic network. This undesirable sensitivity leads to different simulation results when using numerically different but biochemically equivalent stoichiometry representations and thereby makes biological interpretation intrinsically subjective and ambiguous. We hereby propose a new method, Minimization of Metabolites Balance (MiMBl), which decouples the artifacts of stoichiometry representation from the formulation of the desired objective functions, by casting objective functions using metabolite turnovers rather than fluxes. By simulating perturbed metabolic networks, we demonstrate that the use of stoichiometry representation independent algorithms is fundamental for unambiguously linking modeling results with biological interpretation. For example, MiMBl allowed us to expand the scope of metabolic modeling in elucidating the mechanistic basis of several genetic interactions in *Saccharomyces cerevisiae*.

One of the challenging tasks in systems biology is to quantitatively predict the metabolic behavior of the cell under given genetic and environmental constraints. To this end, genome-scale metabolic reconstructions and simulation tools are indispensable. The choice of the objective function to be used for simulating genome-scale metabolic models is dependent on the biological context and one of the most relevant parameters for successful modeling. Formulation of the intended objective function often requires the use of multiple fluxes, e.g. the sum of fluxes through ATP-producing reactions. We demonstrate that the existing tools confound biological interpretation of the simulations due to undesired dependence on the representation of stoichiometry and propose a new tool – Minimization of Metabolites Balance (MiMBl). MiMBl allows casting of the desired biological objective functions into linear optimization models and gives consistent simulation results when using numerically different but biochemically equivalent stoichiometry representations. We demonstrate relevance of MiMBl for addressing biological questions through improved predictions of genetic interactions within the yeast metabolic network. Genetic interactions imply functional relationship between the genes and therefore allow assessing different hypotheses for the underlying biological principles. MiMBl explains several of the genetic interactions as outcome of flux re-routing for minimal metabolite turnover adjustments.

The fundamental role of metabolism within a living cell has become a focal point of study in many disciplines, such as cell biology, physiology, medicine and synthetic biology. The assembly of all reactions and metabolites into a genome-scale metabolic network provides a comprehensive structural framework for integrative data analysis [1], [2], as well as for quantitative modeling of cellular metabolism [3]–[6]. As the solution space for the metabolic flux state of the cell is typically very large, constraint based optimization approaches are often applied for simulating metabolic fluxes. In essence, these approaches search for an optimal flux distribution that maximizes or minimizes an appropriate biological objective function while satisfying the mass balance and metabolite exchange constraints. Among these, Flux Balance Analysis [7] is a widely used simulation tool that utilizes a linear programming formulation for maximization of growth (synthesis of biomass constituents) as biological objective function. FBA has been applied with various degrees of success, albeit mostly for “wild-type” or unperturbed metabolic networks [8], [9]. In addition to FBA, various other objective functions are frequently used, including minimization of overall intracellular flux and maximization of ATP yield, among others. An overview of various commonly used objective functions and their evaluation against experimental data for *Escherichia coli* can be found in Schuetz *et al.*
[10]. In case of genetically or environmentally perturbed networks, Minimization of Metabolic Adjustment algorithm - MoMA [11] - has been reported to better represent the biological observations [11]–[14]. The hypothesis underlying MoMA is that fluxes in a perturbed cell (*e.g.* a mutant) will be redistributed so as to be as similar as possible to the wild-type.

The biological principles exemplified by simulation tools for both wild-type and perturbed networks are undeniably fascinating, which is confirmed by their numerous applications – including prediction of genetic interactions [2], [15], [16], metabolic engineering [13], [14], [17], microbial community modeling [18], [19] and search for evolutionary constraints in relation to different objective functions [20]. Several of the objective functions commonly used in these and other applications rely on the use of linear combination of fluxes, e.g., MoMA or minimization of overall intracellular flux (**Table 1**). We found that the mathematical formulation of this class of problems (*i.e.* where linear combination of fluxes is part of the objective function) is sensitive to the representation of the reaction stoichiometry, with results strongly dependent on the adopted scaling of the stoichiometric coefficients. Such dependency confounds the biological interpretation of simulation results, as biochemically equivalent alternative representations of the same network can lead to contradictory predictions upon a given genetic or environmental perturbation. For example, the status of a given gene may change from non-essential to essential while using biochemically equivalent representations of the stoichiometry of the metabolic network (**Table S1**). As the stoichiometric representation of any reaction is subjective (often scaled to have coefficient of 1 for one of the reactants/products) and a typical genome-scale modeling problem involves hundreds of reactions, there are infinitely many biochemically equivalent ways to represent a given metabolic network. Any simulation algorithm should therefore be independent of the stoichiometry representation.

We motivate the need for rethinking the problem formulation for metabolic modeling by illustrating how the current methods lead to incoherent biological predictions when alternatively representing the reaction stoichiometry. Tackling a proper problem formulation, we propose a new methodology for metabolic modeling – **Mi**nimization of **M**etabolites **B**a**l**ance (MiMBl), which accounts for reaction stoichiometry in the objective function by mapping the flux space into the metabolite turnover space. As intended, MiMBl shows robust predictions independently of the stoichiometry representation. We demonstrate the biological relevance of the new formulation with increased power for predicting genetic interactions in the metabolic network of *S. cerevisiae*. In a recent study reporting a large genetic interactions dataset covering the *S. cerevisiae* metabolic network [2], FBA was found to have limited capability for predicting the experimentally observed interactions, partially due to the lack of regulatory information. Within this study we successfully challenged MiMBl to accomplish the task of extending the range of genetic interactions that can be predicted. By combining the results from MiMBl and FBA, we probe the operating mechanisms underlying genetic interactions within metabolic networks.

Several of the biological objective functions widely used in metabolic modeling are currently formulated as linear (or quadratic) combination of fluxes. Minimization of sum of intracellular fluxes and minimization of metabolic adjustment belong to this class and are herein used as case studies of biological principles that can be robustly formulated by using MiMBl. Two different genome-scale reconstructions of the *S. cerevisiae* metabolic network are used, viz. *i*FF708 [21] and *i*AZ900 [22], as the choice of the appropriate metabolic reconstruction depends on the biological question to be addressed (**Methods**).

Minimization of the sum of intracellular flux is a routinely used objective function for estimating intracellular fluxes [10], [20], [23], [24]. By using the *i*FF708 *S. cerevisiae* genome-scale metabolic reconstruction [21] together with experimentally determined exchange rate constraints (**Text S1**), we illustrate how the use of this objective function leads to inconsistent predictions when using numerically different, but biochemically equivalent, reaction stoichiometry. Linear scaling of all stoichiometric coefficients of a given reaction (*e.g.* multiplication by a scalar θ, **Methods**) preserves the stoichiometry and must not affect the simulation outcome for a correct problem formulation. However, in this case, scaling of a single reaction (RPI1) results in diverting the carbon flow from glycolysis to pentose phosphate pathway, which is one of the most important metabolic branch points (**Fig. 1**). This deviation was verified not to be consequence of alternative optima of the same mathematical solution (**Fig. S2**), thus representing different biological solutions.

In order to provide insight into the nature of the problem leading to the susceptibility of the solution towards alternative representation of the stoichiometric matrix, we use a toy-model depicted in **Fig. 2a**. As a case study, minimization of metabolic adjustment was chosen as biological principle and formulated as minimization of Manhattan distance (a commonly used formulation of MoMA, termed lMoMA [25]). **Fig. 2** also illustrates the representation dependency of the Euclidean distance formulation of MoMA (quadratic MoMA, as originally proposed in [11]). In order to provide an intuitive insight, the following discussion is centered on lMoMA. Similar explanation holds true in quadratic space in the case of quadratic MoMA. In the wild-type toy-model, flux goes from *A* to *D* via *R5*. The goal is to predict flux distribution in the mutant lacking *R5*. The biological principle of minimization of metabolic adjustment dictates rewiring of the flux through *R6*. However, lMoMA found contradictory optimal solutions, *i.e.* solutions that re-route the flux via *R2–R3–R4* or *R6*, depending on the stoichiometric representation of *R6* (**Fig. 2b**). Insight into the cause of this behavior can be gained by analyzing the optimal objective function values, *i.e.* distances, as function of θ* _{R6}* (

The mathematical caveat illustrated above means that the contribution of the desired biological objective function towards the obtained solution is inseparable from that of the artifacts of stoichiometry representation. Importantly, in large metabolic networks the effects of stoichiometric representation of reactions are cumulative. As we herein show, this problem can be solved by proper normalization of the objective function variables with respect to stoichiometric representation of the reactions. To achieve such normalization, we devised two approaches, normalized lMoMA (normlMoMA) and Minimization of Metabolites Balance (MiMBl). In normlMoMA, each variable in the objective function is normalized by its value in the wild-type flux distribution. Albeit being simple, this normalization method has three major drawbacks: i) many reactions often have null fluxes in the wild-type, thus posing a problem for normalization (**Methods, Text S2** and **Fig. S3**); ii) it requires a reference flux distribution to obtain the normalization factors, making it inappropriate to formulate objective functions such as minimization of overall intracellular flux; and iii) the influence of each flux on the metabolic adjustment would be exclusively due to its fold change, not taking into account that reactions carrying higher fluxes could have a stronger impact on the predicted flux distribution, as implied in the original concept of minimization of metabolic adjustment.

To obtain a biological meaningful and mathematically robust normalization, we propose Minimization of Metabolites Balance (MiMBl) as a new method for metabolic modeling. The objective function in MiMBl is formulated as a linear combination of metabolite turnovers (t_{M}). The turnover of a metabolite is the sum of all fluxes producing (or consuming) it, multiplied by the corresponding stoichiometric coefficients (**Methods**). The objective function for minimization of metabolic adjustment is reformulated to include metabolite turnovers instead of fluxes (**Fig. 2c**). Because the stoichiometric coefficients are taken into account while calculating t_{M}, MiMBl is robust to the linear scaling of the stoichiometric matrix, analytical proof of which is presented in the **Methods** section. In case of the toy-model (**Fig. 2a, d**), this robustness is illustrated by the invariant nature of the objective function as well as the flux distribution. Note that the flux through R6 linearly scales with θ* _{R6}*, while the turnover of all metabolites is conserved. The normalization implied in MiMBl formulation is suitable for addressing a variety of biological questions involving different objective functions, such as minimization of overall intracellular flux (by using a null vector for wild-type flux distribution) or maximization of ATP yield (by maximizing the ATP turnover for a given substrate uptake rate), among others (

While mapping the flux space into the metabolite space for the objective function formulation, as we do for MiMBl, it is possible that, for a few cases, alternative flux distributions are found around a given metabolite. We therefore introduce a second optimization step that reinforces the proximity to the reference flux distribution. This is achieved by using a normlMoMA routine where the optimal objective function value found in the first MiMBl optimization step is used as an additional constraint (**Methods**). Nevertheless, highly connected metabolites ensure a degree of network connectivity, which is sufficient for decreasing the number of situations where alternative flux distributions around the same metabolite are picked by MiMBl. Indeed, we did not find any case in the simulations performed for this study where growth prediction was altered in the second optimization step. An example case where the second optimization step will be more relevant is simulations involving export of metabolites, where the choice of a particular transporter (as in the reference flux distribution) among several alternative options is desired. A more thorough analysis of MiMBl alternative optima in a genome-scale network is presented below (**Fig. 3**).

In order to estimate the extent to which the lack of normalization of stoichiometric coefficients within the objective function influences the biological interpretation of simulation results, we used lMoMA for simulating gene knockouts in the *S. cerevisiae* genome-scale metabolic model *i*FF708 [21]. In case of single gene knockout, three genes were found to change their status from non-essential to essential while using two biochemically equivalent matrix representations (**Table S1**). For instance, the mutant lacking *YCR012W*, coding for a 3-phosphoglycerate kinase (pPGK1), was predicted to be viable when using the *as-published* representation of the stoichiometric matrix S_{0}
[21], and non-viable while using the biochemically equivalent matrix S_{1} (**Methods**). Based on such contradictory results, conclusions cannot be taken on whether *YCR012W* is predicted to be essential or not. As the number of deleted genes (or other network perturbations) increases, cumulative phenotypic effects related to the functional interactions between the genes are expected to take place and examples as the one mentioned above become even more striking. For triple gene knockouts, more than 200,000 triplets were found such that their predicted phenotype switched from lethal to non-lethal (or vice-versa) for the two biochemically equivalent matrix representations (**Table S1**). From a biotechnological perspective, predictions from genome-scale modeling have direct influence on the choice of gene targets selected for metabolic engineering. By using lMoMA, we identified metabolic engineering strategies (by simulating all possible combinations of knockouts of up to three genes, **Text S1**) for production of two different compounds in yeast: succinate – a native product, and vanillin-glucoside – a heterologous product. Not only a significant fraction of mutants had divergent predictions for product yield when using two biochemically equivalent stoichiometric matrices, but also several highly ranked strategies in one case were low priority targets in the other (**Figs. S4, S5, S6, S7**). Moreover, we also observed that the number of predicted synthetic lethal pairs differed by more than two-fold when using alternative stoichiometric matrix representations (**Table S2**). These inconsistencies have immediate implications on the consequent biological interpretation, as well as on the experimental design, and can be successfully overcome by using MiMBl (**Fig. S4, Table S3**).

The above analysis proved the robustness of MiMBl towards stoichiometric representation of metabolic reactions. However, some degree of uncertainty in the simulation results might still exist, as we shall show here, essentially arising from two main sources (**Fig. S8a**): i) sensitivity of the results towards the initial wild-type flux distribution used as input for minimizing the metabolic distance; and ii) potential non-uniqueness of the linear programming solution while simulating the mutant phenotype, *i.e.* existence of alternative optima. The sensitivity analysis for MiMBl towards both sources of uncertainty was performed using *i*AZ900 reconstruction of the yeast metabolic network, as the same reconstruction is subsequently used to study genetic interactions within the yeast metabolism. Both sources of variability also have impact on lMoMA simulation results (**Fig. S9**).

Firstly, we analyzed the sensitivity towards the wild-type (or reference) flux distribution used as input for minimization of metabolic adjustment. Using an accurate reference flux distribution is crucial for obtaining biologically meaningful simulation results. While some metabolite exchange rates are commonly available as experimentally derived constraints for the wild-type, they are usually not sufficient to uniquely estimate the corresponding intracellular fluxes, *e.g.* by using FBA (**Figs. S8a and S1**). It has been previously shown that the use of alternative optima within the reference flux distribution obtained with FBA can affect the prediction of growth upon gene deletions using quadratic MoMA [11]. We herein performed a similar analysis by using MiMBl. The growth of single gene deletion mutants was simulated with MiMBl while using alternative optimal FBA flux distributions as reference (**Methods**). Similarly to what was previously observed for quadratic MoMA [11], cases were found where the use of alternative FBA flux distributions, as input to MiMBl, influences the growth prediction (**Fig. 3**). 70% of the predictions of single gene deletion phenotypes were consistent across all FBA-alternative-optima used, while the remaining 30% showed dependence on the input reference flux distribution. Use of additional experimentally determined constraints, for instance as obtained with ^{13}C flux analysis, will be useful for reducing the uncertainty in the input flux distribution and thereby in obtaining more robust predictions.

In order to assess the variability due to potential non-uniqueness of the optimal solution obtained with MiMBl (**Fig. S8a**), we performed a flux variability analysis [26]. Biologically, the alternative optima correspond to the existence of alternative pathways that result in equivalent mutant phenotypes with regards to the required metabolic adjustment. For a fixed reference flux distribution, we calculated the range of variability of intracellular fluxes upon constraining the metabolic adjustment (*i.e.* sum of metabolite turnover distance) to its optimal value (**Methods**). All of the tested fluxes were observed to have very low or no variability (v_{i}^{min}/v_{i}^{max}>0.99) across all single gene deletion phenotypes. Utility of the second step of MiMBl was seen in case of the flux through *PGM1* upon deletion of *YOR128C* (**Fig. S8b**). Nevertheless, existence of a unique solution is problem dependent and it should be verified whether the possibility of alternative optima affects the prediction of fluxes of interest. Therefore, we performed an exhaustive analysis of variability of growth prediction across all single gene deletions, as well as all double gene deletions included in the genetic interactions case study. Growth was uniquely predicted in all these cases (**Fig. S8c**).

To what extent MiMBl contributes for increasing biological understandings gained from the application of optimization-based metabolic modeling? To address this question, we used one of the most recent and comprehensive *S. cerevisiae* models, *i*AZ900 [22], to run simulations for single and double gene knockouts and challenged MiMBl to predict the epistasis scores of all significantly interacting non-essential gene pairs reported by Szappanos *et al.*
[2]. Genetic interaction networks are valuable resources towards deciphering the complex genotype-phenotype relationships. A genetic interaction between two genes occurs when the phenotype displayed by a double deletion mutant is different than the one expected based on the phenotypes of the single mutants. Accordingly, two genes can display positive, negative or no interaction. In order to capture most of the biological information contained in the experimental dataset, we used two different objective functions, maximization of growth (FBA) and minimization of metabolic adjustment (MiMBl). FBA is expected to cover situations where maximization of growth is the cellular objective, while MiMBl will account for regulatory effects inherent to the wild-type flux distribution, in the sense that the flux distribution in the perturbed network is kept as close as possible to that of the wild-type. This principle of proximity to the wild-type (or the reference) should partially reflect principles of flux reorganization in genetically perturbed networks. Although, both FBA and MiMBl performed equally well concerning gene essentiality predictions (~60% sensitivity, **Text S1**), the benefit of using MiMBl as a biological objective function became apparent while predicting genetic interactions. This implies that the biological regulatory principle underlying MiMBl is manifested in yeast (under the investigated conditions) at larger network perturbations or less drastic phenotypes than essentiality. When applied for studying genetic interactions, FBA is a conservative method compared to MiMBl, since the parameter used to define and measure genetic interactions is also the objective of optimization, *i.e.*, growth. Within the metabolic network, the existence of several optimal solutions theoretically satisfying maximum biomass formation is often observed. In case of a single/double gene deletion mutant where an alternative optimal pathway exists, FBA will always find such an alternative solution, even though it may not be biologically plausible due to regulatory constraints, and, thereby may miss potential genetic interactions. On the other hand, MiMBl will help in capturing more refined regulatory effects where the loss of growth is a side effect of minimizing the flux rerouting relative to the wild-type.

The subset of experimental genetic interactions involving non-essential genes from the yeast metabolic model contains 2745 interactions (939 positive and 1806 negative) connecting 520 genes (**Text S1, Table S4**). In order to assess the performance of the different algorithms, we carried out a sensitivity *versus* precision analysis. Precision was calculated as the fraction of experimentally validated interactions among all predicted interactions, while the sensitivity represents the fraction of the experimentally validated interactions captured by the predictions (**Text S1**). A computational epistasis score cutoff (ε_{cutoff}) was used to call a particular gene pair to be positively interacting (ε>ε_{cutoff}), negatively interacting (ε<−ε_{cutoff}) or non-interacting (|ε|<ε_{cutoff}) (**Text S1**). The performance of all algorithms (MiMBl, FBA, lMoMA and quadratic MoMA) is summarized as ROC (partial receiver operating characteristic) curves for both, positive and negative epistasis (**Fig. 4**** a, b and Fig. S10**). The sensitivity and precision of the FBA predictions obtained in this study are within the same range as previously reported by Szappanos *et al.*
[2]. MiMBl shows less precision than FBA in case of both positive (~20% and ~30%, respectively) and negative interactions (~50% and ~60%, respectively), but its sensitivity is considerably higher in both cases (~9% *vs* ~4% for positive, **Fig. 4a**; ~5% *vs* ~3% for negative, **Fig. 4b**), which reflects the conservative nature of FBA in predicting genetic interactions. Notably, for the entire range of genetic interaction cutoffs, MiMBl sensitivity and precision are considerably higher than those of lMoMA (**Fig. 4a, b**). The same trend was verified when the originally proposed quadratic MoMA formulation was used (**Fig. S10**). As previously reported by Szappanos and co-workers, lMoMA does not improve FBA predictions. This observation further emphasizes that a proper mathematical formulation of the biological principle (objective function) has a major impact on the ability to interpret *in vivo* observations.

We chose a strict interaction cutoff (|ε_{cutoff}|=0.013) for further analysis of the predicted interactions (**Fig. S11**). For this cutoff, the correctly predicted genetic interactions map contains 142 interactions (73 positive and 69 negative) connecting 86 genes (**Fig. 4f**). MiMBl not only captures all interactions, except one, predicted by FBA, but also contributes with 48 additional interactions (~34% of all accurate predictions). MiMBl predictions thus span almost all of those from FBA (**Fig. 4c**), which we attribute to the fact that many metabolites within the metabolic model are directly contributing to the biomass formation. Consequently, if the turnover of most metabolites is kept constant upon gene deletions, the biomass turnover (growth) will also remain constant. On the other hand, FBA is not able to capture many genetic interactions found by MiMBl (**Fig. 4c**). These will involve mutants where the loss of fitness upon gene deletion is caused by the change from an *in vivo* well-tuned pathway to an alternative pathway containing different metabolites or enzymes. For many of such cases, there are alternative pathways that sustain the same growth as the reference and FBA finds such solutions, regardless of the magnitude of the turnover adjustment that is required for the cell. Because of this feature, MiMBl is capable of capturing a part of the regulatory constraints on the operation of cellular metabolism, which lMoMA failed to capture (**Fig. 4c**).

The regulatory constraints imposed by MiMBl assume even stronger relevance in the case of positive interactions, where MiMBl exclusively accounts for almost 50% of all successfully predicted interactions (**Fig. 4f**). In fact, FBA's ability of predicting positive interactions is limited, as the maximum predicted biomass formation of a double deletion mutant would never be higher than the highest among those predicted for the two single deletion mutants. Thus, if a single deletion mutant has the maximum predicted fitness of 1 (meaning that the fitness of the mutant is the same as that of the wild-type), positive interactions involving the deleted gene will be impossible to predict. As FBA is bound to find the optimal solution that provides the highest growth, single mutants with maximum fitness are much more often predicted than the ones found by MiMBl, where minimal adjustment of the metabolic network is preferred over maintaining maximum growth. Indeed, MiMBl predicts decreased single mutant fitness for twice more gene knockouts than FBA (~38.4 *vs* 18.1%). Consequently, MiMBl also displayed an improved capacity to predict both positive and negative epistasis involving the same gene. More than 80% of the genes display this feature *in vivo*. Interestingly, 30% of the genes involved in MiMBl predicted epistasis interact both positively and negatively, while FBA predicts that only 14% of the genes do so (**Fig. 4f**).

As metabolic networks are featured by several metabolites with a high degree of connectivity, interactions occur between distant pathways in the network. To assess MiMBl's ability to predict such pleiotropic effects, we calculated the network distance between each pair of genes accurately predicted to interact (**Text S1**). MiMBl captured interactions between genes that are significantly more distant than in case of FBA (~40% more distant for negative epistasis, p-value=0.022; ~10% more distant for both positive and negative epistasis, p-value=0.089; **Fig. 4d, e**).

In a metabolic network reconstruction, a group of isoenzymes is represented by a single reaction, which is associated with two or more genes. Simulation-wise, such a reaction will be inactive only when all of the corresponding isoenzyme-coding genes are deleted and deletion of any single gene will not result in a loss of fitness. Thus, in case of a reaction with two isoenzymes, when the deletion of both isoenzyme-coding genes leads to decreased fitness *in silico*, a negative interaction will be predicted. Our analysis captured several of such cases, for example, the negative interactions between *SER3* and *SER33*, as well as between *SAM1* and *SAM2* (**Fig. 4f**). While this gene-deletion-centered approach allows capturing interactions between isoenzyme-coding genes, it is not suited for predicting interactions between two functionally different genes where one (or both) of them have isoenzymes. However, such interactions are often observed *in vivo*, since isoenzymes do not always completely compensate each other's function due to differences in kinetic and/or regulatory characteristics. Although these effects cannot be directly captured using the currently available metabolic modeling tools, we suggest evaluating the metabolic basis of genetic interactions between functionally different genes with isoenzymes by taking a reaction-centered approach. For this purpose, flux through reactions catalyzed by isoenzymes was constrained to zero when at least one of the isoenzyme-coding genes was deleted. This way, five additional genetic interactions involving isoenzymes were correctly captured: a positive interaction between the isoenzyme group *TLK1 & TLK2* and the gene *ARO1*, as well as four negative interactions involving the isoenzyme group *ALD2-ALD6* and other genes from the central carbon metabolism (**Fig. 4f**). These five interactions are thus likely to result from flux rerouting caused by the lack of compensation by the corresponding isoenzymes.

Use of MiMBl not only allowed us to expand the range of genetic interactions predicted by FBA, but also the combined use of these two complementary algorithms enabled finding of relevant interactions where only one or both simulation principles apply. For example, the interaction between *PGK2* and *GDH2*, exclusively captured by MiMBl, is due to balancing of NADH and glutamate, two of the most connected metabolites in the network. As there are alternative pathways for fulfilling NADH and glutamate requirement (despite implying higher metabolic adjustments), FBA could not capture this interaction. A similar effect is observed for the negative interaction between isoenzymes *SER3* and *SER33*. In the absence of both genes, FBA predicts the needed supply of serine to be totally fulfilled by rerouting the metabolic fluxes via the glyoxylate shunt and threonine biosynthesis. On the other hand, MiMBl predicts that the supply of serine will be shared between the two alternative pathways, but the rescue cannot be complete, because the corresponding metabolic adjustment cost overweighs the benefit of increased growth. This prediction is in very good agreement with the experimental verification that the double mutant growth is impaired and can be restored by adding glycine to the medium, which is the intermediate for serine synthesis via glyoxylate or threonine [27].

Overall, our results demonstrate that the use of optimization-based algorithms that are stoichiometry representation independent is fundamental for unambiguously linking modeling results with biological interpretation. To this end, we report a new method for formulating objective functions for metabolic modeling – MiMBl. As a biological case study, we used MiMBl to gain insights into the flux rewiring underlying genetic interactions within the yeast metabolic network. The analysis showed that the combined use of different objective functions is of primary importance in order to achieve a more complete understanding of the operating principles behind complex biological phenomena such as genetic interactions. Indeed, the number of accurately predicted genetic interactions was almost doubled owing to the use of MiMBl, highlighting the impact of metabolic adjustment constraints on the operation of perturbed metabolic networks. In conclusion, MiMBl provides a framework for consistent mathematical formulation of biological objective functions and thereby facilitates unraveling of the genotype-phenotype relations in metabolic networks.

The susceptibility of the modeling results towards the stoichiometry representation is inherent to the formulation of the objective function; and it is independent of the choice of metabolic network reconstruction. Two reconstructions were therefore selected in this study based on their suitability for addressing the biological principle in question. *i*FF708 [21] was the reconstruction of choice for illustrating the prediction of internal flux distribution and metabolic engineering targets, as i) this reconstruction has been successfully used for model guided metabolic engineering [13], [14] and, ii) when constrained with experimentally measured substrate and product exchange rates [28] (**Text S1**), *i*FF708 showed less flux variability at physiologically important flux nodes as opposed to more recent reconstruction *i*AZ900 [22] (**Fig. S1**). On the other hand, for studying large-scale genetic interactions in yeast, we used *i*AZ900 (manually curated from iMM904 [29]), as the maximum gene coverage overlap with the experimental dataset was the main criterion. Simulation conditions are provided in **Text S1**.

Normalized lMoMa was formulated as follows:

Where *N* is the set of all reactions, *M* is the set of all intracellular metabolites, *S* is the stoichiometric matrix and *v*_{i} is the flux for reaction *i*. *WT* stands for wild-type (or reference), *v _{i}^{lb}* and

Metabolite turnover is defined as the sum of all fluxes producing (or consuming) it, multiplied by the stoichiometric coefficients:

N_{m} is the subset of N producing or consuming metabolite *m* and α* _{m,i}* is the stoichiometric coefficient of metabolite

MiMBl was formulated as two sequential linear programming problems, as follows:

- 1
^{st}optimization: - 2
^{nd}optimization:

We note that MiMBl integrates reaction-to-metabolite turnover mapping into the model formulation in terms of defining biological objective functions and thereby making metabolite-usage a determinant for the prediction of metabolic phenotypes. This formulation is thus different from metabolite-centric approaches that have been proposed for interpreting simulation results [30]–[32].

Alternative stoichiometry representations were obtained by multiplying a given reaction (or a set of reactions) by a scalar θ (or a set of scalars). Consider reaction r , for which an equivalent representation is given by:

where *Y, X* and *Z* represent the metabolites participating in reaction *r* and *α _{Yr}, α_{Xr}, α_{Zr}* represent the corresponding stoichiometric coefficients. Note that when the stoichiometry of reaction

The impact of scaling the constraints of a given linear programming problem depends on whether such changes guarantee the optimality conditions after scaling. Consider the problem:

Where is the cost coefficient of variable in the objective function. Here, a linear combination of non-normalized fluxes is used in the objective function, similarly to *e.g.* minimization of intracellular flux and lMoMA. Assuming that is an optimal basis matrix for the problem, the following optimization condition is satisfied:

where is the index of variable in matrix , is the reduced cost of the variable , is the objective function coefficient of , is the vector containing the objective coefficients of basic variables and is the *j ^{th}* column of matrix
[33]. Linear scaling the problem by the matrix will result in the following reduced cost for each variable:

Where is a positive diagonal matrix (**scaling matrix**) and is the scaling factor for the *j ^{th}* column of matrix . In the cases of entries the corresponding columns of are accordingly scaled. Analogously, is the scaling matrix corresponding to the basic variables.

Unless all entries of are identical,

Therefore the **optimality condition is not guaranteed**.

**Corollary 1**: When all (diagonal) entries of are identical (uniform scaling matrix), and therefore equal to , the optimality condition is simplified to

The same optimality condition can thus be guaranteed only when the matrix is uniformly scaled. Note that due to the nature of the biological problem, the genuine representation of might not be known, thereby cannot be guaranteed to be a uniform scaling matrix. More importantly, for metabolic modeling purposes (where flux units and ranges are problem dependent), it is nevertheless undesirable that the solution is sensitive to non-uniform scaling and thus context dependent.

**Corollary 2**: For any positive diagonal scaling matrix , the same optimality condition is still guaranteed if the cost coefficients vector is also scaled by . However, the choice of the appropriate for formulating a biologically meaningful problem will require existence of a unique representation of for any given network, which is not possible due to subjective nature of stoichiometry representation.

Now consider the following MiMBl-like formulated problem:

Where, is cost coefficient of variable in the objective function. The new problem biologically corresponds to the previous one, after mapping the flux space into metabolite space. We term it as a MiMBl-like problem formulation.

Recall that is the stoichiometric coefficient of metabolite in reaction . The objective function can be re-written as function of :

Therefore, the objective function coefficient of each is a function of the stoichiometric coefficients :

Similarly to the previous problem, the following optimality condition is satisfied, so is an optimal solution.

Scaling the optimality condition will result in:

Unlike the previous situation (sum of fluxes in the objective function), using a MiMBl-like problem formulation guarantees that the optimality condition is always satisfied, independently of the stoichiometry representation.

The sensitivity of MiMBl and lMoMA towards the use of FBA alternative optima for wild-type flux distribution was evaluated by performing single gene deletion simulations while using 500 different flux distributions corresponding to alternative optima of the same FBA solution. FBA alternative optimal solutions were obtained following a Mixed Integer Linear Programming (MILP) routine similar to the one suggested by Lee *et al.*
[34]. Flux variability analysis of the flux distributions obtained with MiMBl and lMoMA were performed according to the procedure suggested by Mahadevan *et al.*
[26]: maximizing and minimizing internal fluxes after constraining the objective function to its optimal value. In case of MiMBl, this implies adding an additional constraint of the minimum Manhattan distance between the wild-type and the mutant metabolite turnovers. In case of lMoMA, the Manhattan distance between the mutant and the wild-type fluxes will have an upper bound. Growth is uniquely predicted if . Cases of =0 were also treated as =1, solely for the purpose of visualization (**Fig. 3d**).

Comparing the variability of predicted internal fluxes of glycolysis and pentose phosphate pathway between the models *i*FF708 and *i*AZ900. Metabolites uptake and production rates, as well as growth from [28] were used to constraint both models and a flux variability analysis as suggested by [26] was performed for the represented fluxes from a) glycolysis and pentose b) phosphate pathway. Flux names are represented as in *i*FF708 [21].

(TIF)

Click here for additional data file.^{(479K, tif)}

Profiles obtained for the objective function value (minimization of overall intracellular flux) using alternative stoichiometry representations of *S. cerevisiae* genome-scale model *i*FF708 [21]. This analysis is complementary to and based on the same simulation constraints as used for **Fig. 1** in the main text. As the contribution of each flux to the objective function changes based on the corresponding stoichiometry representation, different situations could be described, leading either to the same (a, b) or distinct (c, d) optimal solutions. To illustrate these different situations, four reactions within the model were linearly scaled one at a time by multiplying by a scalar θ as described in **Methods**. **a**) Linear scaling of the reaction *FBP1*. As *FBP1* carries no flux under the simulated conditions, the scaling of this reaction does not affect the objective function value. **b**) Linear scaling of the reaction *RPE1*. For the range of θ tested, the objective function value perfectly correlated with the scaling factor of the reaction *RPE1*, which indicates that all obtained solutions are in fact the same optimal solution (or alternative optimal solutions, depending on the model complexity). This profile means that there is no pathway alternative to *RPE1* that can become part of the optimal solution. **c**) Linear scaling of the reaction *RPI1*. For the range of tested θ, at least two slopes are observed when correlating the objective function value with 1/θ, indicating that at least two different optimal solutions were found for the same problem. **d**) Linear scaling of the reaction *NDI1*. Similarly to that of *RPI1*, scaling of *NDI1* leads to different optimal solutions. However, in this case, the objective function value stabilizes after a given θ, which means that this flux no longer influences the optimization. Such profile suggests that the optimal solution found after the given value of θ does no longer involve *NID1*, but an alternative pathway, which became preferred for minimizing the objective function.

(TIF)

Click here for additional data file.^{(407K, tif)}

A toy-model illustrating how, and why, alternative stoichiometry representations influence simulation of minimization of metabolic adjustment by using normalized lMoMA – normlMoMA. **a**) Toy-model: *R1* to *R7* and *A* to *D* represent reactions and metabolites, respectively. In the wild-type, or reference, flux goes from *A* to *D* via *R5*. *R6* and *R2–R3–R4* are two alternative pathways for flux re-distribution after deletion of *R5*. **b**) Flux through reactions *R2* (full symbols) and *R6* (open symbols) obtained after simulation with normlMoMA by using alternative representations of reaction *R6* (given by different θ* _{R6}*,

(TIF)

Click here for additional data file.^{(173K, tif)}

Impact of stoichiometry representation on the design of metabolic engineering strategies depending on the nature of the objective function formulation – MiMBL versus lMoMA. Shown is the comparison of predicted succinate and vanillin-glucoside yields for triple gene knockout mutants obtained with two alternative stoichiometric matrices (*S _{0}* and

(TIF)

Click here for additional data file.^{(246K, tif)}

Stoichiometry representation impacts the design of metabolic engineering strategies for improving succinate production in *S. cerevisiae* depending on the nature of the objective function formulation. Shown is the comparison of predicted succinate yield for **a**) single, **b**) double and **c**) triple gene knockout mutants obtained with two alternative stoichiometric matrices (*S _{0}* and

(TIF)

Click here for additional data file.^{(440K, tif)}

Stoichiometry representation impacts the design of metabolic engineering strategies for improving vanillin-glucoside production in *S. cerevisiae* depending on the nature of the objective function formulation. Shown is the comparison of predicted vanillin-glucoside yield for **a**) single, **b**) double and **c**) triple gene knockout mutants obtained with two alternative stoichiometric matrices (*S _{0}* and

(TIF)

Click here for additional data file.^{(467K, tif)}

Stoichiometry representation impacts the design of metabolic engineering strategies for improving succinate and vanillin-glucoside yields in *S. cerevisiae* depending on the nature of the objective function formulation. **a–f**) Number of mutants diverging in their lMoMA-predicted a–c) succinate and d–f) vanillin-glucoside yields for two alternative representations of stoichiometry, *S _{0}* and

(TIF)

Click here for additional data file.^{(682K, tif)}

Alternative optima and sensitivity to reference flux distribution. **a**) The left side of the panel illustrates the variability due to possible uncertainty in the reference flux distribution, for example, as obtained by FBA simulations. The right hand side of the panel illustrates variability in the simulation result owing to the possibility of alternative optimal solutions of the MiMBL linear programming problem. Deletion of Gene 1 illustrates a case where a unique optimal solution is found, while deletion of Gene 2 depicts a case of alternative optima. **b**) Flux variability analysis to assess the existence of the alternative optimal solutions for a given reference flux distribution (Methods). Shown are the flux variability ranges of alanine transport and flux through phosphoglucomutase (PGM1) after deletion of YBL045C and YOR128C, respectively. PGM1 represents a case where the 2nd optimization step of MiMBL contributes to reducing of flux variability. The corresponding results for lMoMA are presented in Fig. S9. **c**) Flux variability analysis for growth flux following single/double gene deletions. MiMBL yielded unique growth prediction for single and double gene deletion mutants. Only double gene deletions relevant for the genetic interactions case study (main text) were simulated.

(TIF)

Click here for additional data file.^{(548K, tif)}

Alternative optima and sensitivity to reference flux distribution: lMoMA. **a**) Sensitivity of MiMBL towards the use of different reference flux distributions (**Methods**). Shown are histograms of the simulated growth (v_{Growth}/) of the mutants lacking *YLR377C* or *YGL148W* obtained with MiMBL across 500 simulations using alternatively optimal FBA solutions. Gray arrows mark the minimum and the maximum ratio. **b**) Flux variability analysis to assess alternative optimal solutions for a given reference flux distribution (**Methods**). Shown are the flux variability ranges of alanine transport and flux through phosphoglucomutase (PGM1) after deletion of *YBL045C* and *YOR128C*, respectively. PGM1 represents a case where the 2^{nd} optimization step of MiMBL contributes to reducing of flux variability.

(TIF)

Click here for additional data file.^{(154K, tif)}

ROC (partial receiver operating characteristic) curves obtained for predicting genetic interactions with MoMA. The ROC curves for the remaining algorithms were kept for reference. Sensitivity reflects the fraction of experimentally validated interactions captured by the algorithm while precision is experimentally validated interactions among all predicted interactions. **a**) Positive interactions. **b**) Negative interactions.

(TIF)

Click here for additional data file.^{(365K, tif)}

Sensitivity and precision for predicted genetic interactions versus epistasis score cutoff for FBA and MiMBL. The top plots present the sensitivity for positive (**a**) and negative (**b**) interactions for FBA and MiMBL. The epistasis score cutoff of |0.13| is represented by a dashed line. The bottom plots present the precision for positive (**c**) and negative (**d**) interactions for FBA and MiMBL. The epistasis score cutoff of |0.13| is represented by a dashed line.

(TIF)

Click here for additional data file.^{(421K, tif)}

Number of lMoMA-predicted lethal gene/reaction knockouts in *S. cerevisiae* that differ between alternative representations of stoichiometry (S_{1} and S_{2}), relative to S_{0}.

(DOCX)

Click here for additional data file.^{(14K, docx)}

lMoMA-predicted epistatic interactions within *S. cerevisiae* genome-scale metabolic model.

(DOCX)

Click here for additional data file.^{(13K, docx)}

MiMBL-predicted epistatic interactions within *S. cerevisiae* genome-scale metabolic model.

(DOCX)

Click here for additional data file.^{(13K, docx)}

All significant genetic interactions among non-essential genes from Szappanos *et al.* involving genes contained in *i*AZ900 model included in the study.

(XLSX)

Click here for additional data file.^{(1.6M, xlsx)}

Supplementary methods. i) Yeast genome-scale metabolic models and simulation conditions; ii) Flux Balance Analysis; iii) Minimization of overall intracellular flux; iv) Minimization of metabolic adjustment – lMoMA; v) Genetic interactions – epistasis score; vi) Metabolic network distance.

(DOCX)

Click here for additional data file.^{(41K, docx)}

Supplementary notes. i) Toy-model; ii) normlMoMA; iii) Impact of scaling stoichiometry on finding the optimal solution for metabolic flux distributions using FBA-like objective functions – Analytical evidence.

(DOCX)

Click here for additional data file.^{(52K, docx)}

Authors are grateful to A. Zelezniak, A. Montagud, E. Valentini, S. Sheridan and M. Beck for insightful comments and discussions.

ARB acknowledge PhD research grant from Fundação para a Ciência e Tecnologia (ref. SFRH/BD 579/41230/2007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

1. Zelezniak A, Pers TH, Soares S, Patti ME, Patil KR (2010) Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes. PLoS Comput Biol 6: e1000729. [PMC free article] [PubMed]

2. Szappanos B, Kovács K, Szamecz B, Honti F, Costanzo M, et al. (2011) An integrated approach to characterize genetic interaction networks in yeast metabolism. Nat Genet 43: 656–662doi:10.1038/ng.846. [PMC free article] [PubMed]

3. Kümmel A, Panke S, Heinemann M (2006) Putative regulatory sites unraveled by network-embedded thermodynamic analysis of metabolome data. Mol Sys Biol 2: 2006.0034. [PMC free article] [PubMed]

4. Oberhardt MA, Palsson BØ, Papin JA (2009) Applications of genome-scale metabolic reconstructions. Mol Syst Biol 5: 320. [PMC free article] [PubMed]

5. Jerby L, Shlomi T, Ruppin E (2010) Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Sys Biol 6: 401. [PMC free article] [PubMed]

6. Osterlund T, Nookaew I, Nielsen J (2011) Fifteen years of large scale metabolic modeling of yeast: Developments and impacts. Biotechnol Adv 30: 979–88. [PubMed]

7. Varma A, Palsson BØ (1993) Metabolic capabilities of Escherichia coli: I. Synthesis of biosynthetic precursors and cofactors. J Theor Biol 165: 477–502. [PubMed]

8. Ibarra RU, Edwards JS, Palsson BO (2002) Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth. Nature 420: 20–23. [PubMed]

9. Famili I, Förster J, Nielsen J, Palsson BØ (2003) Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network. Proc Natl Acad Sci U S A 100: 13134–13139. [PubMed]

10. Schuetz R, Kuepfer L, Sauer U (2007) Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli. Mol Sys Biol 3: 119. [PMC free article] [PubMed]

11. Segrè D, Vitkup D, Church GM (2002) Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci U S A 99: 15112–15117. [PubMed]

12. Kuepfer L, Sauer U, Blank LM (2005) Metabolic functions of duplicate genes in Saccharomyces cerevisiae. Genome Res 15: 1421–1430. [PubMed]

13. Asadollahi M, Maury J, Patil KR, Schalk M, Clark A, et al. (2009) Enhancing sesquiterpene production in Saccharomyces cerevisiae through in silico driven metabolic engineering. Metab Eng 11: 328–334. [PubMed]

14. Brochado AR, Matos C, Møller BL, Hansen J, Mortensen UH, et al. (2010) Improved vanillin production in baker's yeast through in silico design. Microb Cell Fact 9: 84. [PMC free article] [PubMed]

15. Suthers PF, Zomorrodi A, Maranas CD (2009) Genome-scale gene/reaction essentiality and synthetic lethality analysis. Mol Sys Biol 5: 301. [PMC free article] [PubMed]

16. Snitkin ES, Segrè D (2011) Epistatic Interaction Maps Relative to Multiple Metabolic Phenotypes. PLoS Genetics 7: e1001294. [PMC free article] [PubMed]

17. Alper H, Jin Y-S, Moxley JF, Stephanopoulos G (2005) Identifying gene targets for the metabolic engineering of lycopene biosynthesis in Escherichia coli. Metab Eng 7: 155–164. [PubMed]

18. Zomorrodi AR, Maranas CD (2012) OptCom: A Multi-Level Optimization Framework for the Metabolic Modeling and Analysis of Microbial Communities. PLoS Comput Biol 8: e1002363. [PMC free article] [PubMed]

19. Wintermute EH, Silver P (2010) Emergent cooperation in microbial metabolism. Mol Sys Biol 6: 407. [PMC free article] [PubMed]

20. Schuetz R, Zamboni N, Zampieri M, Heinemann M, Sauer U (2012) Multidimensional Optimality of Microbial Metabolism. Science 336: 601–604. [PubMed]

21. Förster J, Famili I, Fu P, Palsson BØ, Nielsen J (2003) Genome-scale reconstruction of the Saccharomyces cerevisiae metabolic network. Genome Res 13: 244–253. [PubMed]

22. Zomorrodi AR, Maranas CD (2010) Improving the iMM904 S. cerevisiae metabolic model using essentiality and synthetic lethality data. BMC Syst Biol 4: 178. [PMC free article] [PubMed]

23. Blank LM, Kuepfer L, Sauer U (2005) Large-scale 13C-flux analysis reveals mechanistic principles of metabolic network robustness to null mutations in yeast. Genome Biol 6: R49. [PMC free article] [PubMed]

24. Lewis NE, Hixson KK, Conrad TM, Lerman J a, Charusanti P, et al. (2010) Omic data from evolved E. coli are consistent with computed optimal growth from genome-scale models. Mol Sys Biol 6: 390. [PMC free article] [PubMed]

25. Becker S a, Feist AM, Mo ML, Hannum G, Palsson BØ, et al. (2007) Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox. Nat Protoc 2: 727–738. [PubMed]

26. Mahadevan R, Schilling CH (2003) The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. Metab Eng 5: 264–276. [PubMed]

27. Otero JM (2009) Industrial Systems Biology and Metabolic Engineering of Saccharomyces cerevisiae. Göteborg: Chalmers University of Technology. pp. 1–12.

28. Van Hoek P, Van Dijken JP, Pronk JT (1998) Effect of Specific Growth Rate on Fermentative Capacity of Baker's Yeast. Appl Environ Microb 64: 4226–4233. [PMC free article] [PubMed]

29. Mo ML, Palsson BO, Herrgård MJ (2009) Connecting extracellular metabolomic measurements to intracellular flux states in yeast. BMC Syst Biol 3: 37. [PMC free article] [PubMed]

30. Kim P-J, Lee D-Y, Kim TY, Lee KH, Jeong H, et al. (2007) Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci U S A 104: 13638–13642. [PubMed]

31. Chung BKS, Lee D-Y (2009) Flux-sum analysis: a metabolite-centric approach for understanding the metabolic network. BMC Syst Biol 3: 117. [PMC free article] [PubMed]

32. Kim TY, Kim HU, Lee SY (2010) Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab Eng 12: 105–111. [PubMed]

33. Bertsimas D, Tsitsiklis JN (1997) Introduction to Linear Optimization. First Edit. Belmont, Massachusetts: Athena Scientific.

34. Lee S, Phalakornkule C, Domach MM, Grossmann IE (2000) Recursive MILP model for finding all the alternate optima in LP models for metabolic networks. Comput Chem Eng 24: 711–716.

35. Knorr AL, Jain R, Srivastava R (2007) Bayesian-based selection of metabolic objective functions. Bioinformatics 23: 351–357. [PubMed]

36. van Gulik WM, Heijnen JJ (1995) A metabolic network stoichiometry analysis of microbial growth and product formation. Biotechnol Bioeng 48: 681–698. [PubMed]

37. Price ND, Reed JL, Palsson BØ (2004) Genome-scale models of microbial cells: evaluating the consequences of constraints. Nat Rev Microbiol 2: 886–897. [PubMed]

Articles from PLoS Computational Biology are provided here courtesy of **Public Library of Science**

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |